Barclays analyst Michael Leithead maintains Element Solutions (NYSE:ESI) with a Overweight and lowers the price target from $22 to $21.
Bristol Myers Squibb’s Abecma Becomes First CAR T Approved For Use In Earlier Lines Of Therapy For Patients With Relapsed Or Refractory Multiple Myeloma In Japan
Bristol Myers Squibb's Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in JapanTOKYO, December 6, 2023 - Bristol-Myers Squibb
